NCT07142980

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

A Phase I Study of HRS-7172 Evaluating Safety, Tolerability and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.

Conditions

• Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

Type	Name	Description
DRUG	HRS-7172 Tablets	HRS-7172 tablets.

Timeline

• Start date: 2025-09-12
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2025-08-27
• Last updated: 2025-11-17

Locations

1 site across 1 country: China